

Remarks

Pfizer

Applicants' Attorney hereby states that the changes made in the sequence listing, do not include new matter. Support for this amendment is found, *inter alia*, in Figure 1 as originally filed. In particular, a typographical error in SEQ ID NO:1 caused the misalignment of the amino acid sequence with the corresponding nucleotide sequence between nucleotides 562 and 618. Specifically, nucleotides 562 to 564 of SEQ ID NO:1 encode a Gln, however this amino acid was inadvertently inserted underneath nucleotides 616 to 618. As a result, the amino acid sequence and nucleotide sequence are misaligned by one amino acid residue between nucleotides 562 and 618 in SEQ ID NO:1.

The corresponding inadvertent error also occurred in SEQ ID NO:2 and has been corrected in the substitute Sequence Listing submitted herewith. Specifically, the amino acid residue 102 has been corrected to Gln. The Gln amino acid at position 120 has been deleted. The amino acid residues at positions 102 to 119 (in SEQ ID NO:2 as filed) were shifted one position (i.e., to positions 103 to 120). Support for this amendment is found, *inter alia*, in Figure 1 as originally filed.


Applicants' undersigned attorney has amended the specification only to direct the entry of this corrected Sequence Listing between the specification and the claims of the above-identified application.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

It is respectfully requested that this amendment be entered as it does not contain new matter.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Kimberlin L. Morley
Attorney for Applicants
Registration No. 35,391

Date: Dec 3, 1998

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600



P:\USERS\KMORLEY\1488\115\subsseqlist
SKGF Rev. 6/3/98 mac